202 related articles for article (PubMed ID: 16056005)
1. The evolving use of cost-effectiveness analysis in formulary management within the Department of Veterans Affairs.
Aspinall SL; Good CB; Glassman PA; Valentino MA
Med Care; 2005 Jul; 43(7 Suppl):20-6. PubMed ID: 16056005
[TBL] [Abstract][Full Text] [Related]
2. Formulary management in the Department of Defense.
Trice S; Devine J; Mistry H; Moore E; Linton A
J Manag Care Pharm; 2009 Mar; 15(2):133-46. PubMed ID: 19236127
[TBL] [Abstract][Full Text] [Related]
3. Application of pharmacoeconomics to formulary management in a health system setting.
Studdert AL; Gong CL; Srinivas S; Chin AL; Deresinski S
Am J Health Syst Pharm; 2019 Feb; 76(6):381-386. PubMed ID: 31361838
[TBL] [Abstract][Full Text] [Related]
4. The arrival of economic evidence in managed care formulary decisions: the unsolicited request process.
Neumann PJ
Med Care; 2005 Jul; 43(7 Suppl):27-32. PubMed ID: 16056006
[TBL] [Abstract][Full Text] [Related]
5. Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol.
Bukstein DA
Am J Manag Care; 1997 Nov; 3(11):1701-6. PubMed ID: 10178468
[TBL] [Abstract][Full Text] [Related]
6. The formulary decision-making process in a health maintenance organisation setting.
Shepherd MD; Salzman RD
Pharmacoeconomics; 1994 Jan; 5(1):29-38. PubMed ID: 10146864
[TBL] [Abstract][Full Text] [Related]
7. Ontario's formulary committee: how recommendations are made.
PausJenssen AM; Singer PA; Detsky AS
Pharmacoeconomics; 2003; 21(4):285-94. PubMed ID: 12600223
[TBL] [Abstract][Full Text] [Related]
8. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
Kessler JM
Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610
[No Abstract] [Full Text] [Related]
9. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report.
Fry RN; Avey SG; Sullivan SD
Value Health; 2003; 6(5):505-21. PubMed ID: 14627057
[TBL] [Abstract][Full Text] [Related]
10. A call for fairness in formulary decisions.
Levinson W; Laupacis A
Arch Intern Med; 2006 Jan; 166(1):16-8. PubMed ID: 16401806
[No Abstract] [Full Text] [Related]
11. The role of pharmacoeconomic guidelines for formulary approval: the Australian experience.
Langley PC
Clin Ther; 1993; 15(6):1154-76; discussion 1120. PubMed ID: 8111812
[TBL] [Abstract][Full Text] [Related]
12. Managed care guidelines for the economic evaluation of pharmaceuticals.
Langley PC; Martin RE
Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366
[TBL] [Abstract][Full Text] [Related]
13. Pharmacy Benefits Management in the Veterans Health Administration Revisited: A Decade of Advancements, 2004-2014.
Aspinall SL; Sales MM; Good CB; Calabrese V; Glassman PA; Burk M; Moore VR; Neuhauser MM; Golterman L; Ourth H; Valentino MA; Cunningham FE
J Manag Care Spec Pharm; 2016 Sep; 22(9):1058-63. PubMed ID: 27579828
[TBL] [Abstract][Full Text] [Related]
14. The impact of a national prescription drug formulary on prices, market share, and spending: lessons for Medicare?
Huskamp HA; Epstein AM; Blumenthal D
Health Aff (Millwood); 2003; 22(3):149-58. PubMed ID: 12757279
[TBL] [Abstract][Full Text] [Related]
15. Do drug formulary policies reflect evidence of value?
Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
[TBL] [Abstract][Full Text] [Related]
16. Application of pharmacoeconomics to formulary decision making in managed care organizations.
Suh DC; Okpara IR; Agnese WB; Toscani M
Am J Manag Care; 2002 Feb; 8(2):161-9. PubMed ID: 11858228
[TBL] [Abstract][Full Text] [Related]
17. Use of pharmacoeconomic data in making hospital formulary decisions.
Odedina FT; Sullivan J; Nash R; Clemmons CD
Am J Health Syst Pharm; 2002 Aug; 59(15):1441-4. PubMed ID: 12166044
[TBL] [Abstract][Full Text] [Related]
18. Pharmacy benefits management in the Veterans Health Administration: 1995 to 2003.
Sales MM; Cunningham FE; Glassman PA; Valentino MA; Good CB
Am J Manag Care; 2005 Feb; 11(2):104-12. PubMed ID: 15726858
[TBL] [Abstract][Full Text] [Related]
19. Managing conflicts of interest in pharmacy and therapeutics committees: A proposal for multicentre formulary development.
Friesen P; Caplan AL; Miller JE
J Clin Pharm Ther; 2020 Apr; 45(2):249-255. PubMed ID: 31657022
[TBL] [Abstract][Full Text] [Related]
20. Opioid overdose education and naloxone distribution: Development of the Veterans Health Administration's national program.
Oliva EM; Christopher MLD; Wells D; Bounthavong M; Harvey M; Himstreet J; Emmendorfer T; Valentino M; Franchi M; Goodman F; Trafton JA;
J Am Pharm Assoc (2003); 2017; 57(2S):S168-S179.e4. PubMed ID: 28292502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
